Teva Pharmaceutical Industries Net Acquisitions/Divestitures 2010-2024 | TEVA
Teva Pharmaceutical Industries annual/quarterly net acquisitions/divestitures history and growth rate from 2010 to 2024. Net acquisitions/divestitures can be defined as the total change in cash resulting from both investments in businesses and sales of businesses or business segments.
- Teva Pharmaceutical Industries net acquisitions/divestitures for the quarter ending December 31, 2024 were $-0.015B, a INF% decline year-over-year.
- Teva Pharmaceutical Industries net acquisitions/divestitures for the twelve months ending December 31, 2024 were $-60M, a INF% decline year-over-year.
- Teva Pharmaceutical Industries annual net acquisitions/divestitures for 2024 were $-0.015B, a INF% decline from 2023.
- Teva Pharmaceutical Industries annual net acquisitions/divestitures for 2023 were $0B, a 100% decline from 2022.
- Teva Pharmaceutical Industries annual net acquisitions/divestitures for 2022 were $-0.007B, a INF% decline from 2021.
Teva Pharmaceutical Industries Annual Net Acquisitions/Divestitures
(Millions of US $) |
| 2024 |
$-15 |
| 2023 |
$ |
| 2022 |
$-7 |
| 2021 |
$ |
| 2020 |
$ |
| 2019 |
$ |
| 2018 |
$ |
| 2017 |
$43 |
| 2016 |
$-36,148 |
| 2015 |
$-3,309 |
| 2014 |
$-363 |
| 2013 |
$-39 |
| 2012 |
$ |
| 2011 |
$-6,561 |
| 2010 |
$-4,951 |
| 2009 |
$ |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$17.427B |
$16.544B |
|
Teva Pharmaceutical Industries Limited is a global pharmaceutical company that develops, manufactures, and markets both branded and generic drugs, as well as active pharmaceutical ingredients in North America, Europe, Latin America, India, and Israel. Teva's generic product portfolio includes tablets, capsules, liquids, ointments, creams, liquids, injectables, and inhalants. The company's branded products include Copaxone, Austedo, respiratory products like ProAir and Qvar and Ajovy. Teva operates through three segments, North America, Europe and International Markets, each of which includes generics, specialty and over-the-counter products. Teva acquired Allergan's generics business Actavis Generics. The company also acquired Allergan's Anda Inc. Teva acquired Auspex Pharmaceuticals and Barr. Teva has strengthened its position in Europe through its acquisition of Germany's second largest generics producer, ratiopharm.
|
